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Abstract
Background: While conventionally fractionated radiation therapy alone is an acceptable option for poor
prognostic patients with unresectable stage III NSCLC, we hypothesized that accelerated hypofractionated
radiotherapy will have similar efficacy without increasing toxicity.
Methods: This is a retrospective analysis of 300 patients diagnosed with stage III NSCLC treated between 1993 and
2009. Patients included in the study were medically or surgically inoperable, were free of metastatic disease at
initial workup and did not receive concurrent chemotherapy. Patients were categorized into three groups. Group 1
received 45 Gy in 15 fractions over 3 weeks (Accelerated Radiotherapy (ACRT)) while group 2 received 60-63 Gy
(Standard Radiation Therapy 1 (STRT1)) and group 3 received > 63 Gy (Standard Radiation Therapy (STRT2)).
Results: There were 119 (39.7%) patients in the ACRT group, 90 (30.0%) in STRT1 and 91 (30.3%) in STRT2. More
patients in the ACRT group had KPS ≤ 60 (p < 0.001), more commonly presented with weight loss > 5% (p =
0.002), and had stage 3B disease (p < 0.001). After adjusting for clinical variables, there were no differences in the
radiation groups in terms of the patterns of local or distant tumor control or overall survival. Some benefit in
relapse free survival was seen in the STRT1 group as compared to ACRT (HR = 0.65, p = 0.011). Acute toxicity
profiles in the ACRT were significantly lower for grade ≥ 2 radiation dermatitis (p = 0.002), nausea/vomiting (p =
0.022), and weight loss during treatment (p = 0.020).
Conclusions: Despite the limitations of a retrospective analysis, our experience of accelerated hypofractionated
radiation therapy with 45 Gy in 15 fractions appears to be an acceptable treatment option for poor performance
status patients with stage III inoperable tumors. Such a treatment regimen (or higher doses in 15 fractions) should
be prospectively evaluated using modern radiation technologies with the addition of sequential high dose
chemotherapy in stage III NSCLC.
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Background
Worldwide, lung cancer is the leading cause of cancer-
related deaths with approximately 1.4 million deaths
annually [1]. Approximately 80% of these cases are from
non-small cell lung cancer (NSCLC). The current stan-
dard treatment approach for medically or surgically
inoperable NSCLC is once-daily radiation treatments to
60 Gy at 2 Gy per fraction, established by Radiation
Therapy Oncology Group (RTOG) 7,310 trial[2]. It has
been proven subsequently that disease outcome can be
further improved by the addition of concurrent che-
motherapy as demonstrated recently by the publication
of RTOG 9410[3]. However, for more elderly patients
with poor prognostic factors including initial weight loss
≥ 5%, Karnofsky performance status (KPS) scores < 70,
and additional health comorbidities, the standard
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studies have identified initial performance status and
weight loss to be important prognostic factors in pre-
dicting survival in NSCLC [4]. As such, these factors
become important in assessing treatment options for
these patients.
More than half of patients who are diagnosed with
NSCLC are over the age of 65. Concurrent chemoradia-
tion given for six weeks may be difficult for these
patients to tolerate, especially those presenting with
poor performance status and significant weight loss
from their cancers. In addition, many of these patients
present with a host of co-morbid illnesses, making clini-
cians less inclined to treat with full course radiation and
concurrent chemotherapy. Several studies have demon-
strated significant rates of increased toxicity and overall
poorer survival in elderly patients with poor prognostic
factors, raising the need for alternative treatment man-
agement in patients who cannot tolerate standard ther-
apy [5].
Currently, patients with poor prognostic factors are
commonly treated with radiation therapy alone since
concurrent chemotherapy is usually not tolerated. A
study by Nguyen et al. [6] performed at our institution
reported our initial experience in patients treated with
accelerated hypofractionated radiotherapy (ACRT).
Patients were separated into two treatment categories
based on their performance status and initial % weight
loss. Patients with a KPS score ≥ 7 0a n dw e i g h tl o s s≤
5% were treated conventionally (60-66 Gy at 2 Gy per
fraction, N = 29). Patients with poor performance status
and weight loss > 5% were treated with ACRT (45 Gy at
3 Gy per fraction, N = 26). The study showed no statis-
tically significant difference in treatment response rates,
locoregional control and overall survival between the
two treatment arms. Treatment toxicity was also not
found to be different between the two groups. With this
initial experience, 45 Gy became an option at our insti-
tution for patients who could not tolerate the standard
regimen.
For this study, we report our updated experience in
stage III NSCLC patients treated with 45 Gy in 15 frac-
tions and compared to patients who received 60 Gy or
higher conventionally fractionated radiation therapy. We
investigated the efficacy, toxicity, recurrence rate and
survival rates of the ACRT regimen compared to the
more conventionally fractionation radiotherapy.
Methods
Patient characteristics
We reviewed treatment records of 2,657 patients treated
for lung cancer at MD Anderson Cancer Center
between 1993 and 2009. Out of these patients, 1,982
individuals received conventional fractionation (≥ 60
Gy) and 655 patients received accelerated radiation ther-
apy (45 Gy). Staging was based on the American Joint
Committee Classification (AJCC) 7th edition criteria.
We confined our analysis to patients who had histologi-
cally confirmed stage IIIA-IIIB NSCLC that were not
previously treated and did not receive concurrent che-
motherapy. Patients with small cell lung cancer, thymic
tumors and carcinoid were excluded. In all, 300 patients
formed the study cohort. All patients in the study
cohort were able to complete treatment. KPS scores
prior to treatment were recorded based on physicians’
notes. Initial percent weight loss from the disease was
recorded based on patient reports. Information of tumor
s i z ew a sg a t h e r e df r o mt h ei m a g i n gr e p o r t s .T h i sp o s t
hoc analysis was approved by the institutional review
board of MD Anderson.
Of the 300 patients identified for the study, 119
patients received accelerated radiotherapy (ACRT), at 45
Gy in 15 fractions over 3 weeks, 90 patients received
standard radiation therapy at 60-63 Gy in 6 weeks
(STRT1), and 91 individuals received standard radiation
therapy > 63 Gy in 6 weeks (STRT2). All patients were
Computed Tomography (CT) simulated and immobi-
lized using the standard techniques at our institution.
Treatment and outcomes assessment
CT and Positron Emission Tomography (PET) were pri-
marily used to evaluate for disease recurrences following
treatment. Scanned documents and imaging reports
from outside facilities were also used to evaluate for pat-
terns of failure. Pathology reports were used when avail-
able. Both local and distant failures were recorded for
all patients. Dates of death were found by scanned fol-
low up letters in patients’ medical records and the social
security death index.
Radiation treatment toxicity was collected using pro-
gress notes as well as longer-term follow up notes to
assess for radiation-induced side effects. The Common
Terminology Criteria for Adverse Events (CTCAE) v4.03
grading system was used to assign a numerical number
to clinicians’ notes.
Statistical analysis
Chi-squared test (when expected counts ≥ 5 for all cells
of the cross table) or Fisher’s exact tests (when expected
counts < 5 for some cells) were used to assess the asso-
ciations between categorical variables and radiation ther-
apy groups. Wilcoxon tests were used to assess the
association between age and radiation treatment groups.
Overall survival (OS) interval was calculated from the
date of diagnosis to the date of death or last known date
that the patient was alive. Recurrence Free Survival
(RFS) interval was calculated from the date of diagnosis
to the date of relapse, or the date death or last known
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were considered competing risk events. OS and RFS
were first examined by the method of Kaplan and
Meier. The hazard ratios of radiation therapy groups
were computed by a Cox model proportional hazards
model [7], adjusted for induction chemotherapy and
initial weight loss, as well as other variables selected by
the backward selection procedure. The following vari-
ables were examined: age at diagnosis, gender, KPS,
grade, adjuvant chemotherapy, N-stage, T-stage, and
overall clinical stage. Variables were selected by the
backward selection with an adjusted p-value not greater
than 0.1.
Cumulative incidence estimates of disease recurrence
were estimated by subdistribution analysis of competing
risks [8]. Competing risk regression models [8] were
used to assess the association between failures and
radiation therapy groups. For locoregional control, we
adjusted for age. For distant recurrence, we adjusted for
age, and histology.
Results
Patient characteristics
Among the 300 patients, 159 (53.0%) were male, 141
(47.0%) were female. Median age at diagnosis was 69.5
years (range 41-100 years). As of the most recent fol-
low-up, there were 254 (84.7%) deaths. There were 165
(55%) patients who experienced one or both local (n =
77) and distant failures (n = 119). Overall, 188 patients
(62.7%) died without locoregional failure, 148 (49.3%)
died without distant failure, and 108 individuals (36.0%)
died without evidence of disease recurrence.
Patient and tumor characteristics are summarized in
Table 1. Patients in the ACRT group more commonly
had KPS scores ≤ 70 and an initial weight loss ≥ 5%.
These patients more often had stage 3B vs. 3A disease.
Patients receiving 60-63 Gy presented with a similar
median age compared to the ACRT cohort. In this
group both genders were more equally represented, with
KPS scores ranging between 70 and 80; they more often
presented with weight loss < 5%. These patients more
Table 1 Patient/Treatment Characteristics
Variable ACRT STRT1 STRT2 Total p-value
(45 Gy) (60-63 Gy) (> 63 Gy)
n = 119 n = 90 n = 91
Age median(range) 68(41,100) 67(44,88) 73(47,95) 69.5(41,100) < 0.001
Gender Female 48(40.3%) 43(47.8%) 50(54.9%) 141(47.0%) 0.108
Male 71(59.7%) 47(52.2%) 41(45.1%) 159(53.0%)
Smoking Status Never 8(6.8%) 2(2.2%) 4(4.4%) 14(4.7%) 0.224
Quit 70(59.8%) 45(50.6%) 53(58.2%) 168(56.6%)
Current 39(33.3%) 42(47.2%) 34(37.4%) 115(38.7%)
Karnofsky Performance Status score 90 3(2.5%) 5(5.6%) 6(6.6%) 14(4.7%) < 0.001
80 35(29.4%) 58(64.4%) 40(44.0%) 133(44.3%)
70 47(39.5%) 23(25.6%) 38(41.8%) 108(36.0%)
≤ 60 34(28.6%) 4(4.4%) 7(7.7%) 45(15.0%)
Presenting Weight No 56(51.4%) 67(75.3%) 61(67.8%) 184(63.9%) 0.002
loss ≥ 5% Yes 53(48.6%) 22(24.7%) 29(32.2%) 104(36.1%)
Tumor Stage IIIA 37(31.1%) 50(55.6%) 57(62.6%) 144(48.0%) < 0.001
IIIB 82(68.9%) 40(44.4%) 34(37.4%) 156(52.0%)
Tumor Histology Adenocarcinoma 37(31.4%) 31(35.2%) 41(45.6%) 109(36.8%) 0.142
Squamous 42(35.6%) 34(38.6%) 32(35.6%) 108(36.5%)
NSC-NOS 39(33.1%) 23(26.1%) 17(18.9%) 79(26.6%)
Tumor Grade Well 3(2.5%) 0(0%) 4(4.4%) 7(2.3%) 0.069
Moderate 11(9.2%) 12(13.3%) 10(11.0%) 33(11.0%)
Poor 37(31.1%) 42(46.7%) 29(31.9%) 108(36.0%)
Unclear 68(57.1%) 36(40.0%) 48(52.7%) 152(50.7%)
Tumor Size (cm) median(range) 5(1,11.5) 5(1.5,10.5) 4.2(1,9) 5(1,11.5) 0.039
Induction No 96(80.7%) 29(32.2%) 64(70.3%) 189(63.0%) < 0.001
Chemotherapy Yes 23(19.3%) 61(67.8%) 27(29.7%) 111(37.0%)
Adjuvant No 105(88.2%) 85(94.4%) 86(94.5%) 276(92.0%) 0.15
Chemotherapy Yes 14(11.8%) 5(5.6%) 5(5.5%) 24(8.0%)
ACRT: accelerated radiotherapy; STRT1: standard radiation therapy 1 (60-63 Gy); SBRT2: standard radiation therapy 2 (> 63 Gy); NSC-NOS: Non-Small Cell-Not
Otherwise Specified
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tistically significant higher rate of induction chemother-
apy. Patients receiving > 63 Gy were older, had KPS
scores ≥ 80, weight loss < 5%, and with stage 3A and 3B
more evenly distributed (Table 1).
Locoregional and distant recurrence rates
Under univariable analysis, locoregional failure and dis-
tant recurrence rates were not significant between
radiation treatment (RT) groups, with similar cumula-
tive incidence of failures for all groups (Figure 1A
&1B). Age as a continuous variable was found to be a
significant predictor for locoregional (Hazard Ratio
[HR] 0.979, 95% Confidence Interval [CI] 0.969-0.999,
p = 0.039) and distant failures (HR 0.967, 95% CI
0.967-0.999, p = 0.041). In addition, non-small cell
lung cancer-not otherwise specified (nsc-nos) (HR
1.656, 95% CI 1.028-2.667, p = 0.038) and adenocarci-
noma (HR 1.601, 95% CI 1.029-2.492, p = 0.037), when
compared to squamous carcinoma histology, predicted
for increased rates of distant failure. Under multivari-
able analysis, adjusting for age and histology, RT
groups were again not significantly associated with
locoregional or distant failures. However, younger age
was significantly associated with locoregional failures,
and younger age and histology (adenocarcinoma versus
squamous) were independent predictors for distant
metastasis (Table 2).
Relapse free survival and overall survival
Under univariable analysis, relapse free survival (RFS)
was better for those in the STRT2 group (Figure 2A).
After adjusting for age, induction chemotherapy, initial
weight loss and tumor histology under multivariable
analysis, STRT1 had improved RFS compared to
ACRT1 but no difference was seen between ACRT and
STRT2. Age and tumor histology were also found to be
independent predictors for RFS (Table 3).
For overall survival, RT groups were significantly dif-
ferent under univariable analysis (Figure 2B), with
STRT1 having the better overall survival outcome.
Lower KPS was a predictor for worse OS (p = 0.005).
Receipt of adjuvant chemotherapy was not a predictor
for OS (p = 0.988). After adjusting for factors such as
age, induction chemotherapy, and initial weight loss, RT
groups did not differ significantly between ACRT
$ %
Figure 1 Cumulative incidence representing rate of local-regional recurrence (Figure 1A) and distant failure (Figure 1B) for all patients
based on radiation treatment groups.
Table 2 Multivariable Analysis for Locoregional Failure and Distant Metastasis
Locoregional Failure Distant Metastasis
Variable Level HR (95% CI) p-value (multivariable) HR (95% CI) p-value (multivariable)
RT Group STRT1 vs. ACRT 0.797 (0.455-1.398) 0.430 0.821 (0.520-1.296) 0.400
STRT2 vs. ACRT 1.267 (0.742-2.164) 0.390 1.216 (0.792-1.867) 0.370
STRT2 vs. STRT1 1.590 (0.890-2.840) 0.120 1.482 (0.930-2.361) 0.098
Age years, continuous 0.976 (0.957-0.996) 0.021 0.982 (0.965-0.999) 0.037
Tumor Histology NSC-NOS vs. Squamous - - 1.525 (0.933,2.494) 0.092
Adenocarcinoma vs. Squamous - - 1.551 (0.996, 2.415) 0.052
HR: Hazard Ratio; CI: Confidence Interval; RT: Radiation Treatment; NSC-NOS: Non-Small Cell-Not Otherwise Specified
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independent predictor for worse OS (Table 3).
Treatment toxicity
Treatment was generally well tolerated in all radiation
therapy groups. Toxicity profiles in the 45 Gy group
were significantly lower for several categories in com-
parison to the 60-63 Gy and > 63 Gy groups (Table 4).
Grade 2 and greater radiation dermatitis, nausea and
vomiting, and weight loss during treatment were all sig-
nificantly less in the ACRT group. Pneumonitis was the
most common toxicity found in all three groups, though
about 10% less in the ACRT treatment arm. No differ-
ences were appreciated in rates of pneumonitis, esopha-
gitis or dysphagia.
Discussion
S i n c et h eo r i g i n a ls t u d yb yN g u y e ne ta l .[ 6 ] ,o u ri n s t i -
tution has been using 45 Gy in 15 fractions for unre-
sectable NSCLC who otherwise cannot tolerate the
conventional regimen. In that original report, and
presently in this updated study with a much larger
study cohort, patients receiving accelerated radiother-
apy had comparable local and distant recurrence rates
with no difference in overall survival compared to con-
ventionally fractionated radiotherapy for all stages
combined, even though these patients initially pre-
sented with worse prognostic factors. Our study
showed no difference in cumulative incidence of locor-
egional or distant failures between the RT groups in
the presence of competing factors. There was some
difference in relapse free survival in the 60-63 Gy arm
with no difference in overall survival after adjusting for
other variables. Lastly, we found treatment to be well
tolerated in the ACRT cohort, even though these
patients presented with worse prognostic factors
( w e i g h tl o s s>5 % ,K P S<7 0 ) .O v e r a l l ,o u rs t u d y
demonstrates that accelerated radiation therapy with
45 Gy in 15 fractions is an acceptable treatment option
with comparable outcomes for patients with inoperable
tumors treated with conventional radiotherapy without
chemotherapy.
$ %
Figure 2 Kaplan-Meier curves representing recurrence free survival (Figure 2A) and overall survival (Figure 2B) for all patients based
on radiation treatment groups.
Table 3 Multivariate Analysis of Overall and Recurrence Free Survival
Overall Survival Relapse Free Survival
Variable Level HR (95% CI) p-value
(multivariable)
HR (95% CI) p-value
(multivariable)
RT Group (All stages) STRT1 vs. ACRT 0.764 (0.544-1.074) 0.121 0.649 (0.465-0.904) 0.011
STRT2 vs. ACRT 0.885 (0.643-1.219) 0.455 0.848 (0.619-1.162) 0.304
Induction Chemotherapy Yes vs. No 0.852 (0.637-1.139) 0.280 0.896 (0.675-1.189) 0.445
Initial Weight Loss ≥ 5% vs. < 5% 1.192 (0.909-1.562) 0.205 1.099 (0.842-1.434) 0.488
Age Each 5 yr 1.122 (1.056-1.193) < 0.001 1.091 (1.026-1.987) 0.005
Tumor Histology NSC-NOS vs.
Adenocarcinoma
- - 1.428 (1.026-1.987) 0.035
Squamous vs.
Adenocarcinoma
- - 1.180 (0.879-1.584) 0.271
HR: Hazard Ratio; CI: Confidence Interval; RT: Radiation Treatment; NSC-NOS: Non-Small Cell-Not Otherwise Specified
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tionation for the treatment of locally advanced lung can-
cers has been reported in other studies. Slotman et al.
[9] retrospectively compared three hypofractionated
schemes for the treatment of unresectable NSCLC
(stage IIIA-IV) (40 Gy split course, 30-32 Gy in 6 frac-
tions, or 24 Gy in 3 fractions) demonstrated that a split
course treatment regimen of 40 Gy had improved over-
all survival and lower local relapse rates in stage IIIA
NSCLC patients, but not in patients with stage IIIB-IV
disease. Kepka et al. [10] performed a dose escalation
study in which patients were initially treated with a 4
week course (21 days) at 56.7 Gy (2.7 Gy per fraction),
and gradually escalated to a MTD of 60.9 Gy in 21 days
(2.9 Gy per fraction). Fit patients received induction
chemotherapy for 2-3 cycles. The median survival was
17 months, and the 2- and 3-year overall survival rates
were 32 and 19%, respectively.
There are several biological benefits of the 45 Gy in 15
fraction treatment regimen. Applying a/b ratio of 10,
this regimen has a biological equivalent dose (BED10) of
58.5 Gy. Although this is lower than the BED10 for
patients treated with conventionally fractionated radia-
tion to 60-70 Gy (72-84 Gy), our preliminary data pub-
lished by Nguyen et al. [6] and this updated experience
seem to indicate that control rates seem similar between
the two treatment schemes. The benefit may come in
the shortened treatment time, which can counteract
tumor repopulation. Many studies have stressed the
importance of maintaining radiation treatment duration
within a shortened period, to prevent tumor repopula-
tion, which often contains more resistant cells that are
much more difficult to treat. The biological benefit of
accelerated radiotherapy can best be seen as a negative
influence factor against rapid tumor cell proliferation.
Cox et al. [11] showed a significant difference in OS in
patients with treatment delays which were noted to be
more frequent in patients receiving higher total doses (≥
69.6 Gy). Other studies looking at lung cancer patients
also noted potentially worse outcomes with prolonged
radiation treatment times, due in part to repopulation
[12,13].
Our study is limited by its retrospective nature, and
apparent imbalances in the treatment groups that are
inherent in observational studies. Some of our patients
had poor follow-up, and therefore disease recurrence
m a yh a v eb e e nm o r ec o m m o nt h a nr e p o r t e d .H o w e v e r ,
the merits of our study are that this is a review of a
fairly large group of patients (> 100) of a regimen of
hypofractionated accelerated radiotherapy for a group of
patients that would not have otherwise tolerated a
longer course of therapy. The comparison groups were
patients who received > 60 Gy without concurrent che-
motherapy, which we believe, despite the inherent lim-
itations, better answered the issue of dose and removed
the confounding factor of patient selection for the
receipt of concurrent chemotherapy.
We believe our reported experience demonstrated the
tolerability and relative effectiveness of this treatment
regimen. Currently concurrent chemoradiation is the
standard therapy for the management of locally
advanced NSCLC, based on the recently published
phase III trial RTOG 9410 [3]. This regimen improved
the median survival by about 3 months over induction
chemotherapy and conventionally fractionated radiother-
apy. However, this treatment regimen carries substan-
tially higher grade 3 or higher non-hematologic acute
toxicities, such as esophagitis and mucositis. Limiting
concurrent chemotherapy with radiotherapy would
minimize this additive toxicity. Since distant metastatic
Table 4 Toxicity Distribution
Toxicity Grade ACRT STRT1 STRT2 Total p-value
(45 Gy) (60-63 Gy) (> 63 Gy)
n = 154 n = 99 n = 239
Esophagitis 0-1 107(89.9%) 80(88.9%) 82(90.1%) 269(89.7%) 0.958
≥ 2 12(10.1%) 10(11.1%) 9(9.9%) 31(10.3%)
Dysphagia 0-1 110(92.4%) 75(83.3%) 80(87.9%) 265(88.3%) 0.126
≥ 2 9(7.6%) 15(16.7%) 11(12.1%) 35(11.7%)
Pneumonitis 0-1 105(88.2%) 71(78.9%) 71(78.0%) 247(82.3%) 0.093
≥ 2 14(11.8%) 19(21.1%) 20(22.0%) 53(17.7%)
Radiation Dermatitis 0-1 117(98.3%) 79(87.8%) 78(85.7%) 274(91.3%) 0.002
≥ 2 2(1.7%) 11(12.2%) 13(14.3%) 26(8.7%)
Nausea/Vomiting 0-1 115(96.6%) 79(87.8%) 87(95.6%) 281(93.7%) 0.022
≥ 2 4(3.4%) 11(12.2%) 13(14.3%) 26(8.7%)
Weight loss 0-1 115(96.6%) 81(90.0%) 90(98.9%) 286(95.3%) 0.020
≥ 2 4(3.4%) 9(10.0%) 1(1.1%) 14(4.7%)
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advanced NSCLC, treatment using a regimen of high
dose systemic chemotherapy sandwiched with a short
course of effective local therapy may improve disease
outcomes while reducing treatment related toxicities.
Building upon our experience is the basis of an
ongoing dose escalation radiotherapy trial at our institu-
tion using proton beam therapy in advanced lung cancer
patients (45 Gy to 52.5 Gy to 60 Gy in 15 fractions), as
well as a proposed phase II trial using sequential high
dose chemotherapy and the sandwiched hypofractio-
nated radiotherapy using the MTD (from the above
dose escalation trial) in 15 fractions using protons or
IMRT for locally advanced NSCLC. We believe this
approach for the treatment of unresectable lung cancers
can become a standard in the future, by minimizing
both the toxicity of concurrent chemotherapy and the
delay of long course radiotherapy. By shortening the
overall treatment time and allowing full dose systemic
therapy to be delivered sequentially with effective local
radiotherapy may improve the distant metastatic rate
and accelerated repopulation potential.
Conclusions
Our findings suggest that accelerated radiotherapy for
patients with inoperable tumors is a safe, convenient
and effective treatment option. Although this study is
limited by the retrospective nature of the analysis, these
are hypothesis-generating results which can serve as a
basis of a prospective study comparing hypofractionated
regimen with conventionally fractionated radiotherapy.
However, with similar rates of efficacy in high-risk indi-
viduals as seen from these results, a shortened treatment
time interval will reduce overall treatment cost and
improve patient convenience. We believe this treatment
approach will be a viable treatment option for unresect-
able lung cancers in the future in combination with
sequential systemic therapies.
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